CN115605265B - 用于治疗和/或预防与血管紧张素ii相关的疾病、病症或病状的新型化合物 - Google Patents

用于治疗和/或预防与血管紧张素ii相关的疾病、病症或病状的新型化合物

Info

Publication number
CN115605265B
CN115605265B CN202180033927.3A CN202180033927A CN115605265B CN 115605265 B CN115605265 B CN 115605265B CN 202180033927 A CN202180033927 A CN 202180033927A CN 115605265 B CN115605265 B CN 115605265B
Authority
CN
China
Prior art keywords
methyl
sulfonyl
imidazol
phenyl
carbamate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202180033927.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN115605265A (zh
Inventor
A·哈尔伯格
M·拉赫德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Vicore Pharma AB
Original Assignee
Vicore Pharma AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vicore Pharma AB filed Critical Vicore Pharma AB
Publication of CN115605265A publication Critical patent/CN115605265A/zh
Application granted granted Critical
Publication of CN115605265B publication Critical patent/CN115605265B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/64—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN202180033927.3A 2020-03-19 2021-03-18 用于治疗和/或预防与血管紧张素ii相关的疾病、病症或病状的新型化合物 Active CN115605265B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
SE2050301-7 2020-03-19
SE2050301 2020-03-19
SE2050782 2020-06-29
SE2050782-8 2020-06-29
PCT/GB2021/050680 WO2021186185A1 (en) 2020-03-19 2021-03-18 Novel compounds useful in the treatment and/or prevention of a disease, disorder or condition associated with angiotensin ii

Publications (2)

Publication Number Publication Date
CN115605265A CN115605265A (zh) 2023-01-13
CN115605265B true CN115605265B (zh) 2026-01-23

Family

ID=75339995

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180033927.3A Active CN115605265B (zh) 2020-03-19 2021-03-18 用于治疗和/或预防与血管紧张素ii相关的疾病、病症或病状的新型化合物

Country Status (14)

Country Link
US (1) US20230159467A1 (https=)
EP (1) EP4121165A1 (https=)
JP (1) JP2023518948A (https=)
KR (1) KR20230004501A (https=)
CN (1) CN115605265B (https=)
AU (1) AU2021238939A1 (https=)
BR (1) BR112022018549A2 (https=)
CA (1) CA3175559A1 (https=)
CL (1) CL2022002540A1 (https=)
CO (1) CO2022014673A2 (https=)
IL (1) IL296247A (https=)
MX (1) MX2022011613A (https=)
PH (1) PH12022552413A1 (https=)
WO (1) WO2021186185A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4313953A1 (en) * 2021-03-23 2024-02-07 Vicore Pharma AB Selective angiotensin ii receptor ligands
GB202104033D0 (en) * 2021-03-23 2021-05-05 Vicore Pharma Ab New compounds
GB202113583D0 (en) * 2021-09-23 2021-11-10 Vicore Pharma Ab New compounds
MX2024000518A (es) 2021-07-09 2024-01-31 Vicore Pharma Ab Nuevos compuestos selectivos de angiotensina ii.
JP2024178482A (ja) * 2021-11-15 2024-12-25 株式会社アークメディスン 化合物、アンジオテンシンｉｉタイプ１受容体拮抗剤及び医薬組成物
IE20230600A3 (en) 2022-12-22 2025-09-24 Vicore Pharma Ab A method of treating a patient diagnosed with an interstitial lung disease
WO2024149712A1 (en) * 2023-01-09 2024-07-18 Vicore Pharma Ab Selective angiotensin ii compounds
CN119504723A (zh) * 2023-08-25 2025-02-25 武汉人福创新药物研发中心有限公司 作为at2r激动剂的噻吩磺酰基氨基甲酸酯
WO2025146172A1 (zh) * 2024-01-03 2025-07-10 武汉人福创新药物研发中心有限公司 一种并环类化合物作为at2r激动剂
WO2025252142A1 (zh) * 2024-06-07 2025-12-11 江苏柯菲平医药股份有限公司 一种血管紧张素ii型2受体激动剂及其用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
CN1529697A (zh) * 2001-05-31 2004-09-15 ά�ƶ�ҩ�﹫˾ 用作血管紧张素ⅱ激动剂的三环化合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9800550D0 (sv) 1998-02-24 1998-02-24 A & Science Invest Ab A pharmaceutical preparation comprising an angiotensin II type 2 receptor agonist, and use thereof
KR100938817B1 (ko) * 2001-05-31 2010-01-26 바이코어 파마 아베 안지오텐신 ⅱ 작용제로 유용한 삼중고리 화합물
WO2004046141A1 (en) 2002-11-21 2004-06-03 Vicore Pharma Ab New tricyclic angiotensin ii agonists
AU2006235698B2 (en) * 2005-04-12 2012-03-29 Vicore Pharma Ab New tricyclic angiotensin II agonists
US8835471B2 (en) 2010-06-11 2014-09-16 Vicore Pharma Ab Use of angiotensin II agonists
DE102012004589A1 (de) 2012-03-09 2013-09-12 Forschungszentrum Jülich GmbH Agonisten des Angiotensin II AT2-Rezeptors zur Behandlung neurodegenerativer Erkrankungen
BR112017012337A2 (pt) 2014-12-12 2018-02-27 Vicore Pharma Ab Método para tratamento de doença falciforme, agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró- fármaco do mesmo, uso de um agonista do receptor at2, ou um sal farmaceuticamente aceitável, solvato ou pró-fármaco do mesmo, formulação farmacêutica, e, produto de combinação.
WO2016107879A2 (en) 2014-12-30 2016-07-07 Vicore Pharma Ab New use of angiotensin ii receptor agonists
CN107405406A (zh) * 2015-03-02 2017-11-28 维科尔药物公司 用于治疗肺纤维化的血管紧张素ii受体激动剂
WO2017221012A1 (en) 2016-06-21 2017-12-28 Vicore Pharma Ab Methods and compositions for preventing or reducing the risk of cancer treatment-related cardiotoxicity
GB201710906D0 (en) 2017-07-06 2017-08-23 Vicore Pharma Ab Compounds and methods for treating peripheral neuropathy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5198438A (en) * 1991-05-07 1993-03-30 Merck & Co., Inc. Angiotensin ii antagonists incorporating a substituted thiophene or furan
CN1529697A (zh) * 2001-05-31 2004-09-15 ά�ƶ�ҩ�﹫˾ 用作血管紧张素ⅱ激动剂的三环化合物

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Design, Synthesis, and Biological Evaluation of the First Selective Nonpeptide AT2 Receptor Agonist;Wan Yiqian 等;《J.Med.Chem.》;20041015;第47卷(第24期);第5995-6008页 *
Selective angiotensin II AT2 receptor agonists with reduced CYP 450 inhibition;Mahalingam A.K.等;《Bioorganic & Medicinal Chemistry》;20100409;第18卷(第12期);第4570-4590页 *

Also Published As

Publication number Publication date
WO2021186185A1 (en) 2021-09-23
CA3175559A1 (en) 2021-09-23
US20230159467A1 (en) 2023-05-25
IL296247A (en) 2022-11-01
EP4121165A1 (en) 2023-01-25
KR20230004501A (ko) 2023-01-06
CO2022014673A2 (es) 2023-01-16
BR112022018549A2 (pt) 2022-11-29
MX2022011613A (es) 2022-10-21
JP2023518948A (ja) 2023-05-09
CL2022002540A1 (es) 2023-04-21
CN115605265A (zh) 2023-01-13
PH12022552413A1 (en) 2024-01-08
AU2021238939A1 (en) 2022-11-10

Similar Documents

Publication Publication Date Title
CN115605265B (zh) 用于治疗和/或预防与血管紧张素ii相关的疾病、病症或病状的新型化合物
CN114786774A (zh) 新化合物
US12441718B2 (en) Selective angiotensin II compounds
IL300582A (en) New compounds for use in the treatment of angiotensin II-related diseases
WO2022200786A1 (en) Selective angiotensin ii receptor ligands
GB2605148A (en) New compounds
WO2024149712A1 (en) Selective angiotensin ii compounds
EP4313953A1 (en) Selective angiotensin ii receptor ligands
WO2022200787A1 (en) Selective angiotensin ii receptor ligands
EA049950B1 (ru) Новые соединения, используемые для лечения и/или профилактики заболевания, расстройства или состояния, связанного с ангиотензином ii
CN117916229A (zh) 新型选择性血管紧张素ii化合物
CN117222624A (zh) 选择性血管紧张素ii受体配体

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant